ClinicalTrials.gg
RecruitingNCT02455687Updated Mar 22, 2024

Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.

A Phase 3 interventional study of Hi-dose iv MgSO4 and Nebulized budesonide in Bronchial Asthma, sponsored by Hamad Medical Corporation. Recruiting at 1 site in Qatar. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Hamad Medical Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
40th of 108
240 · median 124
Started
2015
with 2 others
Phase 3
51 of 110
3 open now
Registered
80th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 40th largest by planned enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2015, is one of 51 in phase 3, and was the 80th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.

In this 2x2 factorial design blinded randomized study, no interaction of hypothesized treatments is expected.Investigators hypothesize that two doses of intravenous magnesium sulfate,a high dose followed by a (lower) standard dose, will shorten the time to medical readiness for discharge compared to a single standard dose followed by placebo.The second hypothesis is that nebulized inhaled budesonide will be superior to placebo.

Read the detailed description

Patient with a severe asthma attack will be admitted to the observation area in the Pediatric Emergency Center and assessed for eligibility for the study by the attending physician, based upon our study inclusion/exclusion criteria.

Eligible patients will be enrolled after obtaining written consent from the parents. Patients will receive routine treatment for a severe asthma attack, such as inhaled bronchodilators, plus intravenous steroids and supplementary oxygen if needed. Standard blood work and chest X-Ray will be obtained and bronchial asthma severity score will be measured at baseline before starting treatment,and then at 4,8,12,24,36,48 hr and thereafter. The medical team as well as parents and patient will be blinded to the medications delivered. The patient will be randomized into one of the four study groups and adverse effects of the medications in each group will be monitored and documented carefully.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

Keywords

  • Bronchial Asthma
  • Intravenous magnesium sulfate
  • Inhaled budesonide
04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children 2-14 years of age.
  2. Known to have bronchial asthma.
  3. Presenting in severe asthma exacerbation
  4. Asthma severity score 8 or higher according to PRAM asthma severity .

Exclusion criteria

Exclusion Criteria:

  1. Prematurity \<34 weeks of gestation.
  2. Critically ill children requiring immediate intubation or ICU admission.
  3. Transfers from other institutions.
  4. Adverse drug reaction or allergy to budesonide,salbutamol,ipratropium bromide, prednisone, prednisolone, methylprednisolone, or magnesium sulfate.
  5. History of neuromuscular disease, cardiac disease, renal disease, liver disease.
  6. Underlying chronic lung disease.
  7. Radiographic evidence of pneumonia or lung collapse .
  8. Hemodynamic instability.
  9. Instrumented airway or Tracheotomy.
  10. Colostomy or ileostomy.
  11. Malabsorption disorder.
  12. Known vitamin D deficiency.
  13. Receiving Milk of Magnesium for Constipation
  14. Chronic diarrhea (duration for 2 weeks)
  15. Diuretics use.
  16. Immunodeficiency.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Hi-Mg + Bud

    Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.

    Drug: Hi-dose iv MgSO4 · Drug: Nebulized budesonide

  • Placebo comparator
    Hi-Mg + P

    Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.

    Drug: Hi-dose iv MgSO4 · Drug: Nebulized normal saline

  • Active comparator
    Std-Mg + Bud

    Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.

    Drug: Nebulized budesonide · Drug: Std-dose iv MgSO4

  • Placebo comparator
    St-Mg + P

    Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline

    Drug: Std-dose iv MgSO4 · Drug: Nebulized normal saline

Interventions

  • DrugHi-dose iv MgSO4
  • DrugBudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Also known as: Pulmicort

  • DrugStd-dose iv MgSO4
  • DrugNebulized normal saline
06

What researchers measure

Primary outcomes

  1. Time to medical readiness for discharge.

    The aim of the study is to find out if the two doses of intravenous magnesium sulfate 100 mg/kg followed by 50 mg/kg with or without nebulized budesonide would shorten the length of the emergency center's stay in comparison to the 50 mg/kg dose with or without nebulized budesonide in treating severe asthma attack in children, who are admitted to the pediatric emergency center Al-Sadd, in a double blinded randomized controlled trial. .

    Time frame: 3 years

Secondary outcomes

  1. Overall length of the hospital stay (hours/days) .

    Would the two doses of intravenous magnesium sulfate with or without nebulized budesonide shorten the length of the emergency center's stay in treating severe asthma attack in children, compared to the 50 mg/kg dose with or without nebulized budesonide?

    Time frame: 3 years

  2. The rate of admission to pediatric intensive care unit (%)

    Would the two doses of intravenous magnesium sulfate with or without nebulized budesonide decrease the PICU admission rate in treating severe asthma attack in children, compared to the 50 mg/kg dose with or without nebulized budesonide?

    Time frame: 3 years

  3. Comparison of clinical response in severity score (%)

    Would the two doses of intravenous magnesium sulfate with or without nebulized budesonide decrease the asthma severity score at 4, 8,12,24,36,48,60,72 hours in treating severe asthma attack in children, compared to the 50 mg/kg dose with or without nebulized budesonide?

    Time frame: 3 years

  4. Frequency of need for revisit and readmission to pediatric emergency center for same diagnosis(%)

    Would the two doses of intravenous magnesium sulfate with or without nebulized budesonide decrease revisit to emergency services in treating severe asthma attack in children, compared to the 50 mg/kg dose with or without nebulized budesonide? Would the two doses of intravenous magnesium sulfate with or without nebulized budesonide decrease readmission rate in treating severe asthma attack in children, compared to the 50 mg/kg dose with or without nebulized budesonide? •

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Dec 2024, 114 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 114 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2015
First posted
May 28, 2015
StartActual
Jun 2015
Primary completionEst.
Dec 2024
CompletionEst.
Jan 2025
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02455687
Responsible party
Sponsor
First posted
May 28, 2015
Start date
Jun 2015
Primary completion
Dec 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
Mar 22, 2024

Study contacts

Khalid Alansari, MD
Contact
kalansari@hamad.qa
+974-55336166
Faten Abumusa, MD
Contact
fmoussa@hamad.qa
+974-55312922
Khalid Alansari, MD
study director · Sidra Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion